Barbeau Pharma, Inc., located in Evanston, Illinois, develops, gains marketing approval and markets or out-licenses specialty ethical pharmaceuticals. The company pursues the development and regulatory approval of drugs currently on the market which no longer enjoy patent protection and which are experiencing substantial off-label use for patient treatments. With several drugs under development, Barbeau identifies new opportunities for existing, off-patent therapeutics through a strategy of development for new indications that will also have the advantage of marketing protection provided by patents on the reformulated chemical entity or its method of manufacture, the Waxman-Hatch Act, or Orphan Drug regulations. The company focuses on unmet or under-served clinical needs in the areas of migraine prophylaxis, epilepsy and bipolar disorder, acute hypertensive crisis, chemotherapy induced nausea and vomiting, nocturnal incontinence and gastrotintestional disorders.
http://www.archimedespharma.com
Archimedes is a European specialty pharmaceutical company with an established commercial organisation in the UK, France and Germany and a portfolio of products marketed to specialist prescribers. Archimedes' products include Gliadel, for high grade glioma; Zomorph, an oral sustained release morphine product for cancer pain; Nozinan, a neuroleptic with anti-emetic properties, particularly suited to treat nausea and vomiting in advanced cancer patients; and Pabrinex, a high potency formulation of vitamins B and C for alcoholics experiencing acute withdrawal. Archimedes' strategy is to grow its commercial presence organically and through the acquisition of pharmaceutical companies or marketed brands in Europe and through partnering or licensing of European rights to new specialist prescribed products. In parallel, Archimedes is developing a robust pipeline of innovative near term products to support its commercial organisation. Its lead product, NasalFent®, intranasal fentanyl for rapid relief of breakthrough cancer pain, has successfully completed Phase II clinical trials and could be ready for launch in 2009. To provide further impetus and sales growth for the company in the medium term, Archimedes has an established development organisation with proprietary technologies for nasal drug delivery and a number of products in development.
EUSA Pharma is a specialty pharma company with a strong and growing portfolio of specialty hospital medicines. It has been built through the acquisition of Talisker Pharmaceuticals in July 2006 and OPi in March 2007. Our primary marketed products are Erwinase®, Rapydan®, Kidrolase®, Fomepizole and Xenazine®. In addition we have an active development pipeline including candidates in rheumatoid arthritis and Alzheimer's disease, schizophrenia and Lambert Eaton Syndrome. During 2007 EUSA Pharma will have established a marketing capability in the big five European markets as well as Scandinavia, Benelux, Austria, Ireland and Portugal. In addition, Erwinase® is made available to investigators under a treatment IND in the United States. In parallel, merger and acquisition activities are underway to develop an effective US capability facilitating further access to the North American specialty pharmaceutical market.
http://www.agitherapeutics.com
AGI Therapeutics plc (AGI) is a specialty pharmaceutical company. It has a portfolio of product candidates derived from its known molecular entity (KME) approach to drug re-profiling and development. Its lead product candidate, Rezular is an orally administered triple-action intestinal regulator, a mechanism for the treatment of diarrhoea predominant irritable bowel syndrome, (IBS-D). As of December 31, 2007, Rezular is in Phase III clinical trials. AGI is developing a range of product candidates to treat prevalent gastrointestinal diseases and disorders, including irritable bowel syndrome, dyspepsia, gastroparesis, ulcerative colitis, gastro-esophageal reflux disease and diarrhoea-related conditions, such as chemotherapy-induced diarrhoea. In September 2007, it announced that United States Food and Drug Administration (FDA) has accepted its investigational new drug (IND) filing for arverapamil (AGI-003), AGI's treatment for diarrhoea-predominant irritable bowel syndrome (IBS-D). (Source: ARS)
Axcan Pharma is a privately-held, leading specialty pharmaceutical company that develops and markets a wide range of products to treat gastrointestinal diseases and disorders, such as inflammatory bowel disease, cholestatic liver diseases, irritable bowel syndrome, and complications related to pancreatic insufficiency. All Axcan's activities underscore the Company's single, well-defined Mission - to improve the quality of care and health of patients suffering from gastrointestinal diseases and disorders by providing effective therapies for patients and their specialized caregivers. Through internal product development and synergistic acquisitions of products and companies, Axcan has built a leadership position in the North American gastroenterology market; just under 85 percent of the Company's business is generated from North American sales. Since Axcan markets its specialized products to a relatively cohesive community of physicians, its sales forces are able to reach this market more easily than pharmaceutical companies with a product portfolio targeting a more diverse range of diseases. Axcan's products are marketed by its own dedicated and specialized sales forces both in North America and the European Union. Axcan Pharma and its global operations are working hand-in-hand to become a multinational leader for disorders linked to gastroenterology. Currently, the Company markets more than 40 products and dosage strengths worldwide in the field of gastroenterology, including several that hold a leading market position. In addition to its marketing activities, Axcan carries out research and development of products at an advanced stage of development that it acquires or licenses from third parties. By combining its marketing expertise with its research and development experience, Axcan distinguishes itself from specialty pharmaceutical companies that focus solely on the distribution of products and offers potential licensors the prospect of rapidly expanding the market for their products. Axcan's unique expertise in its field, combined with its excellent industry reputation and international reach, has enabled the Company to maintain its consistent growth trend and attain its strong market position. Axcan's solid and stable base business provides a platform for the Company to capitalize on its proven business strategy, in order to continue to achieve significant future growth. The Company plans to continue to grow its business by: increasing market penetration and sales of existing products; developing and obtaining marketing approval for new products; in-licensing products and acquiring new products or companies; development of its research and development portfolio, and expanding geographically. Axcan's corporate headquarters are based outside of Montreal, Quebec, Canada. The Company employs almost 500 people worldwide and has additional offices in both the United States and France.
Eurand N.V. is a specialty pharmaceutical company that develops, manufactures and commercializes pharmaceutical and biopharmaceutical products based on its drug formulation technologies. The Company has applied its technologies to drug products in a range of therapeutic areas, including cardiovascular, gastrointestinal, pain, nutrition and respiratory. In December 2007, it completed the rolling submission of a new drug application (NDA) for its lead product candidate, Zentase (formerly known as EUR-1008), which is being evaluated for the treatment of exocrine pancreatic insufficiency (EPI). The NDA was accepted for filing and granted priority review in February 2008. In addition to Zentase the Company is also developing a number of other products both for its collaboration partners and its portfolio. As of December 2007, the most advanced of its pipeline products include two co-development products and one product candidate. (Source: 20-F)
Privacy Policy | Terms and Conditions | Do Not Sell My Personal Information | Websites Directory
Copyright © 2022 kwtbox.com. All Rights Reserved. US Business Directory